Citigroup Maintains Neutral on 10x Genomics, Raises Price Target to $24

Benzinga Newsdesk www.benzinga.com Neutral 60.9%

Neg 0% Neu 60.9% Pos 0%

Citigroup analyst Patrick Donnelly maintains 10x Genomics (NASDAQ:TXG) with a Neutral and raises the price target from $18 to $24.